NCT00031083View on ClinicalTrials.gov

Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 2, 2002

Study Completion Date

October 10, 2003

Conditions
Glioblastoma MultiformeAnaplastic AstrocytomaOligoastrocytoma, MixedGliosarcoma
Interventions
GENETIC

Interferon-beta

Trial Locations (5)

2114

Massachusetts General Hospital, Boston

19104

Hospital of the University of Pennsylvania, Philadelphia

35294

University of Alabama at Birmingham, Birmingham

80262

University of Colorado Health Sciences Center, Denver

85724

University of Arizona at Tucson, Tucson

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY